Free cash flow was -$1.6B in Q3 2026 (-122.3% margin) against a cash balance that fell to $1.2B, suggesting limited runway and no shareholder returns, with dividends at $0 across the period.
Moderna, Inc. (MRNA) cash flow statement — 10-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 |
|---|
| Cash from Operations | -1.76B | -1.87B | -3B | -3.12B | 4.98B | 13.62B | 2.03B | -458.97M | -330.87M | -331.48M | 66.73M |
| Operating CF Margin % | - | -96.35% | -93.9% | -45.53% | 26.39% | 76.79% | 252.3% | -762.29% | -244.96% | -161.05% | 61.57% |
| Operating CF Growth % | 13.22% | 37.65% | 3.66% | -162.6% | -63.43% | 571.94% | 541.64% | -38.72% | 0.19% | -596.72% | - |
| Net Income | -2.79B | -2.82B | -3.56B | -4.71B | 8.36B | 12.2B | -747.06M | -514.02M | -384.73M | -255.92M | -216.21M |
| Depreciation & Amortization | 257M | 215M | 189M | 621M | 348M | 232M | 31M | 31.02M | 24.86M | 20.54M | 15.11M |
| Stock-Based Compensation | 351M | 483M | 429M | 305M | 226M | 142M | 93M | 81.12M | 72.56M | 40.05M | 39.36M |
| Deferred Taxes | 0 | 0 | 0 | 828M | -559M | -318M | 10.42M | 0 | 0 | 0 | 288K |
| Other Non-Cash Items | 213M | -3M | 17M | -19M | 59M | 54M | 62.56M | -3.43M | -975K | 1.09M | 2.19M |
| Working Capital Changes | 204M | 254M | -78M | -139M | -3.46B | 1.31B | 2.58B | -53.66M | -42.58M | -137.25M | 225.99M |
| Change in Receivables | -325M | 156M | 534M | 493M | 1.79B | -1.78B | -1.39B | 7.22M | 832K | 106K | 52.34M |
| Change in Inventory | 20M | -34M | 83M | 747M | 492M | -1.39B | -46.53M | 7.2M | 4.41M | 34.8M | -582K |
| Change in Payables | -10M | -92M | -69M | 13M | 240M | 204M | 11.88M | -23.96M | 15.02M | -12.77M | 5.99M |
| Cash from Investing | -1.51B | 1.95B | 1.95B | 4.21B | -5.18B | -8.52B | -1.67B | -14.95M | -372.47M | 416.1M | -648.61M |
| Capital Expenditures | -185M | -192M | -1.05B | -707M | -400M | -284M | -67.45M | -31.55M | -105.77M | -58.4M | -33.14M |
| CapEx % of Revenue | 7.33% | 9.88% | 32.85% | 10.32% | 2.12% | 1.6% | 8.4% | 52.41% | 78.31% | 28.37% | 30.58% |
| Acquisitions | 0 | 0 | 0 | -85M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -74M | -10M | 0 | 0 | -40M | -30M | 0 | 0 | 622K | -1.27M | -8.9M |
| Cash from Financing | 3.34B | 593M | 56M | -1.38B | -3.45B | -873M | 2.03B | 51.12M | 1.23B | 168K | 472.91M |
| Debt Issued (Net) | 3.54B | 539M | -10M | -270M | -184M | -140M | -6M | 1M | 9.46M | 1.44M | 0 |
| Equity Issued (Net) | 186M | 35M | 66M | -1.11B | -3.26B | -733M | 2.04B | 50.15M | 1.22B | 212K | 473.53M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.48M | -633K |
| Share Repurchases | -2M | 0 | 0 | -1.15B | -3.33B | -857M | 0 | 2.89M | -8.18M | 0 | 0 |
| Other Financing | -385M | 19M | 0 | 0 | 0 | 0 | 193K | -29K | 0 | 0 | 11K |
| Net Change in Cash | 61M | 668M | -999M | -289M | -3.64B | 4.22B | 2.39B | -422.79M | 523.5M | 84.78M | -108.96M |
| Free Cash Flow | -1.95B | -2.06B | -4.05B | -3.83B | 4.58B | 13.34B | 1.96B | -490.52M | -436.63M | -389.88M | 33.59M |
| FCF Margin % | -77.19% | -106.22% | -126.76% | -55.86% | 24.27% | 75.19% | 243.91% | -814.7% | -323.27% | -189.43% | 30.99% |
| FCF Growth % | 26.81% | 49.08% | -6.01% | -183.5% | -65.65% | 580.57% | 499.48% | -12.34% | -11.99% | -1260.72% | - |
| FCF per Share | -4.53 | -5.31 | -10.56 | -10.01 | 11.01 | 30.94 | 5.14 | -1.48 | -1.33 | -1.04 | 0.52 |
| FCF Conversion (FCF/Net Income) | 0.70x | 0.66x | 0.84x | 0.66x | 0.60x | 1.12x | -2.71x | 0.89x | 0.86x | 1.30x | -0.31x |
| Interest Paid | 0 | 0 | 24M | 39M | 25M | 14M | 9M | 0 | 3M | 0 | 0 |
| Taxes Paid | 0 | 0 | 197M | 0 | 2.73B | 480M | 1M | 0 | 294K | 398K | 905K |
Quick answers to the most common questions about buying MRNA stock.
Moderna, Inc. (MRNA) generated $-1873.0M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Moderna, Inc. (MRNA) reported negative free cash flow of $2.06B in 2025, indicating capital requirements exceeded cash from operations.
Moderna, Inc. (MRNA) spent $192.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Cash burn outpacing commercial recovery
Metrics are mathematically derived from official filings.
Net Income Diverges From Operating Cash Flow
Based on reported quarterly figures, Moderna's operating cash flow was negative in six of the last ten quarters, while net income swung between profit and loss, leaving cash conversion weak and unreliable as an earnings signal.
The gap between net income and operating cash flow is the central issue, as the OCF-to-net-income ratio fluctuates erratically between negative and positive values that do not meaningfully track earnings. The Q3 2026 net income of $162.0M alongside operating cash flow of roughly -$1.6B suggests the reported profit is not translating into cash, and working capital movements of about -$1.9B appear to account for much of that divergence. Investors should treat the quarter's EPS beat with caution until cash generation confirms the earnings quality.
Free Cash Flow Remains Deeply Negative
As reported in the quarterly cash flow statements, Moderna's free cash flow margin was -122.3% in Q3 2026 and has been negative across most recent periods, with only isolated quarters showing positive free cash flow.
Free cash flow has oscillated between large negative readings and occasional positive quarters, most notably the $912M in Q4 2025 and $303M in Q4 2024, which appear tied to working capital timing rather than a sustained operating improvement. The persistent negative trend indicates the business has not yet reached a self-funding level despite the commercial launches. Sustained positive free cash flow would be needed to validate the recovery narrative.
Capex Spikes Reflect Capacity Uncertainty
According to the reported figures, capital expenditure has been modest in most quarters at roughly 2% to 8% of revenue, though it reached 109.3% and 82.4% of revenue in early 2025 and 2024, respectively.
The elevated capex readings in Q1 2025 and Q2 2024 appear to reflect manufacturing investment during periods of revenue weakness, which would be consistent with building capacity ahead of demand. The low capex levels in most recent quarters suggest the company has curtailed infrastructure spending, which may reflect capacity right-sizing. Depreciation of roughly $50M to $70M per quarter remains well below these historical spikes, leaving the asset base relatively unrefreshed.
No Shareholder Returns During Cash Burn
Based on reported cash flow data, Moderna paid no dividends across the ten quarters shown and recorded only minimal buybacks, with acquisition spending not disclosed.
The absence of dividends and near-zero repurchases is appropriate given sustained operating cash outflows, and capital is effectively being preserved to fund the research pipeline. Acquisition spending is not disclosed in the supplied data, so no conclusion can be drawn about inorganic deployment. Investors should monitor whether the company's cash position supports pipeline funding through the period of negative operating cash flow.
Q3 Inflection May Prove Isolated
Based on reported figures, Moderna's trailing net margin of -145.2% and cumulative quarterly losses exceeding $800M in several periods suggest the Q3 2026 profit may be an isolated event rather than the start of sustained profitability.
The Q3 2026 net income of $162.0M contrasts sharply with the operating cash outflow of roughly -$1.6B in the same quarter, indicating that the earnings improvement has not been accompanied by cash generation and may depend on accrual or timing effects. Several recent quarters, including Q2 2024 and Q1 2026, recorded substantial losses, which reinforces the view that one profitable quarter does not establish a durable trend. Investors should treat the inflection thesis as unconfirmed until positive operating cash flow persists across multiple consecutive periods.